Sphere Fluidics has closed a US$2 million (circa £1.5 million) investment round. The company, a Cambridge University spin-off company, secured funding from several investors including Greenwood Way Capital, Oxford Technology and Innovations EIS Fund and 24Haymarket.
The funds raised will be used to accelerate growth in operations and support sales of its Cyto-Mine Single Cell analysis system. The plan, Sphere Fluidics said, is to expand operations and sales capabilities across the UK and in the UK including the opening of a new US West Coast Sales Office.
Sphere Fluidics’ Cyto-Mine is an automated platform that integrates single-cell screening, sorting, dispensing, imaging and clone verification.
It has been designed to process up to 40 million cells per day and assesses and isolates those that produce a specific biologic to help streamline workflows and improve throughput in antibody discovery and cell line development.
Frank Craig, Sphere Fluidics CEO, said: “We are pleased to see such a high level of interest in Sphere Fluidics and receive funding from several leading investors. We are making further investment in automating and streamlining our manufacturing processes across our product range to extend our offering and to deliver our high-quality standards and service to more researchers working in biotherapeutic discovery and cell line development across the UK and USA. We will be raising additional funds to expand these capabilities further.”
Cyto-Mine will be on display in Washington, DC at SLAS 2019. The event takes place on 2-6 February at the Walter E. Washington Convention Center in Washington.